Exelixis, Inc. Appoints Executive Vice President And General Counsel

Published: Feb 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit Exelixis following its first product launch and in anticipation of top-line data from as many as four phase 3 pivotal trials later this year.

Help employers find you! Check out all the jobs and post your resume.

Back to news